Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8446 to 8460 of 8804 results

  1. Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]

    In development Reference number: GID-TA11365 Expected publication date: TBC

  2. Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]

    In development Reference number: GID-TA11021 Expected publication date: TBC

  3. Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]

    In development Reference number: GID-TA10774 Expected publication date: TBC

  4. Iptacopan for treating primary IgA nephropathy [ID6640]

    In development Reference number: GID-TA11844 Expected publication date: TBC

  5. Lower urinary tract symptoms in men, trans and non-binary people with a prostate: assessment and management (update)

    Discontinued Reference number: GID-NG10300

  6. Ruxolitinib for Prurigo Nodularis [ID6571]

    In development Reference number: GID-TA11760 Expected publication date: TBC

  7. Farco-fill Protect for indwelling urinary catheterisation (MIB121)

    July 2021: NICE has withdrawn the medtech innovation briefing (MIB) on Farco-fill Protect for indwelling urinary catheterisation because the product has been withdrawn from the UK market.

  8. Major changes to type 2 diabetes treatment could save thousands of lives

    New guidance means millions of people will get access to medicines that protect the heart and kidneys, while NHS savings of £560 million from using generic dapagliflozin can be reinvested elsewhere in NHS care.

  9. Improving outcomes in urological cancers (CSG2)

    NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.

  10. Improving supportive and palliative care for adults with cancer (CSG4)

    NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.

  11. Improving outcomes in breast cancer (CSG1)

    NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.

  12. Faster, fairer access to HealthTech under new national programme

    People across England and Wales are set to receive faster, fairer access to innovative HealthTech under the new National HealthTech Access Programme (NHAP).

  13. Simple home test prevents thousands of unnecessary bowel cancer referrals

    A simple home test is sparing thousands of people from unnecessary hospital investigations for bowel cancer, while helping them get faster answers about whether they have the disease – with new data showing the impact of NICE's recommendation to use the test.

  14. NICE says paperclip-sized sensor could help thousands monitor heart condition from home

    A wireless sensor the size of a paperclip could transform care for people living with chronic heart failure, enabling them to monitor their condition daily from home and catch warning signs before they become emergencies, NICE has said.